Immuneering announces clinical supply agreement with Eli Lilly

Immuneering (IMRX) announced a clinical supply agreement with Eli Lilly and Company (LLY) for its second-generation KRAS G12C inhibitor, olomorasib. The supply agreement supports the evaluation of Immuneering’s lead product candidate, atebimetinib, a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase 2 clinical trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer, NSCLC, who have progressed on prior therapy. In February 2025, Immuneering announced a clinical trial agreement with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with the anti-PD-1 therapy Libtayo in patients with advanced non-small cell lung cancer. “This agreement with Lilly marks the second such collaboration we have announced this year as we seek to evaluate the potential of atebimetinib in combination with synergistic anti-cancer mechanisms. A pan-MAPK solution is of particular interest in challenging tumor types such as NSCLC,” said E.B. Brakewood Chief Business Officer of Immuneering.